Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial)
Sitravatinib 联合 tislelizumab 治疗局部复发或转移性三阴性乳腺癌：一项多队列、单臂 II 期临床试验（SPARK 试验）
期刊:Molecular Cancer
影响因子:33.9
doi:10.1186/s12943-025-02505-5
Liu, Xi-Yu; Sui, Xin-Yi; Xu, Ying; Yang, Fan; Wu, Song-Yang; Zhu, Xiu-Zhi; Zuo, Ke; Cao, Shuo-Wen; Jin, Xi; Chen, Li; Ma, Lin-Xiaoxi; Zhang, Wen-Juan; Ye, Fu-Gui; Qu, Fei-Lin; Ma, Ding; Xiao, Yi; Di, Gen-Hong; Liu, Guang-Yu; Yu, Ke-Da; Wu, Jiong; Hu, Xin; Jiang, Yi-Zhou; Wang, Zhong-Hua; Shao, Zhi-Ming; Fan, Lei
